we value viralytics at a$0.69/share, page-3

I am assuming this Report will be released to the market.... AND... more importantly, to the USA market.

I would hope so.

The valuation of 69 cents is a strange one and I guess it is difficult to find appropriate criteria upon which to base it.
I found it impossible to follow.... (discounted cash flows up until 2032) but then I personally place all importance on the last sentence on Page 2 of the Report.... "However, given the positive signs of efficacy to date and the potential of a positive readout, the prospects for attracting a big Pharma partner appear promising".

Blind Freddy can see such an outcome would generate multiples of 69 cents.
To me, even attempting to find a formula upon which to arrive at a valuation, is fraught with "under-valuation" risks.